Skip to main content

Table 4 Patient characteristics and incidence of comorbidities of HAM-net-registered patients

From: Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan

HAM-net-registered patients observed for at least one year (n = 434)

Sex: Female

327 (75.3%)

Age at baseline (year)a

61.9 ± 10.6

Age at onset (year)a

44.4 ± 14.8

Disease durationa (time from onset to the baseline)

16.3 ± 11.1

Baseline OMDSa

5.7 ± 2.2

Rapid progressorsb

83 (19.1%)

Comorbidities

Incidence per 1000 person-yearsc

Uveitis

6.5 (3.3–12.7)

Sjogren’s syndrome

0.8 (0.1–4.3)

Rheumatoid arthritis

3.0 (1.2–7.7)

All Bone Fracture

55.5 (44.0–69.8)

 OMDS 1–4

35.9 (19.5–66.1)

 OMDS 5

57.4 (39.2–84.2)

 OMDS 6

73.2 (46.3–115.8)

 OMDS 7–13

56.0 (35.4–88.6)

 Lower limb fracture

22.6 (15.8–32.3)

 OMDS 1–4

3.5 (0.6–19.6)

 OMDS 5

23.7 (13.3–42.5)

 OMDS 6

24.1 (11.1–52.6)

 OMDS 7–13

36.8 (21.0–64.3)

 Compression fracture

22.4 (15.7–32.0)

 OMDS 1–4

10.6 (3.6–31.1)

 OMDS 5

19.3 (10.1–36.6)

 OMDS 6

44.0 (24.6–78.9)

 OMDS 7–13

20.7 (10.0–42.8)

 Upper limb fracture

3.7 (1.6–8.6)

Herpes zoster

10.4 (6.2–17.4)

Interstitial pneumonia

1.5 (0.4–5.4)

Tuberculosis

0.0 (0.0–2.8)

Diabetes mellitusd

6.2 (3.1–12.2)

Cataractd

9.4 (5.4–16.5)

Glaucomad

2.3 (0.8–6.7)

  1. aData are expressed as mean ± standard deviation
  2. bRapid progressors were defined as those who developed OMDS 5 or above within 2 years from the onset of motor symptoms
  3. cData are expressed as point estimates and 95% confidence intervals
  4. dThese data are based on open-ended questions about comorbidities, Abbreviation: OMDS, Osame motor disability score